Payment overview · 2025
General Payments
$770.44
12 reported records · 8 companies
Healthcare provider profile · identity verified
Rajesh Rohatgi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GARDEN CITY, NY · NPI 1932118528
Verified facts
What the public records show
CMS Open Payments records show Rajesh Rohatgi, MD received $770.44 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $352.52 | 45.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $161.66 | 21.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.76 | 13.9% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $59.32 | 7.7% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.97 | 4.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.34 | 3.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.97 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.90 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $770.44 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $237.29 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $161.66 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $115.23 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $106.76 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $59.32 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| Veklury Normalized: veklury |
Drug | Gilead Sciences, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
452 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1131 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 836 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 80 |
| Metformin Hcl | Metformin Hcl | 458 | 91 |
| Eliquis | Apixaban | 452 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 439 | 82 |
| Losartan Potassium | Losartan Potassium | 434 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 69 |
| Furosemide | Furosemide | 388 | 82 |
| Gabapentin | Gabapentin | 361 | 86 |
| Omeprazole | Omeprazole | 349 | 72 |
| Lisinopril | Lisinopril | 348 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 70 |
| Famotidine | Famotidine | 245 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 243 | 44 |
| Simvastatin | Simvastatin | 235 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 51 |
| Donepezil Hcl | Donepezil Hcl | 209 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 44 |
| Levetiracetam | Levetiracetam | 192 | 33 |
| Potassium Chloride | Potassium Chloride | 181 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 172 | 36 |
| Mirtazapine | Mirtazapine | 171 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 40 |
| Januvia | Sitagliptin Phosphate | 164 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 160 | 41 |
| Divalproex Sodium | Divalproex Sodium | 150 | 41 |
| Carvedilol | Carvedilol | 148 | 32 |
| Latanoprost | Latanoprost | 148 | 37 |
| Finasteride | Finasteride | 147 | 31 |
| Allopurinol | Allopurinol | 146 | 27 |
| Memantine Hcl | Memantine Hcl | 139 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 60 |
| Baclofen | Baclofen | 119 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 26 |
| Olanzapine | Olanzapine | 101 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 47 |
| Sertraline Hcl | Sertraline Hcl | 92 | 19 |
| Warfarin Sodium | Warfarin Sodium | 87 | suppressed |
| Azithromycin | Azithromycin | 85 | 75 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 14 |
| Risperidone | Risperidone | 83 | 23 |
| Jardiance | Empagliflozin | 82 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 79 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 21 |
| Spironolactone | Spironolactone | 78 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 12 |
| Enalapril Maleate | Enalapril Maleate | 70 | 13 |
| Hydrocortisone | Hydrocortisone | 70 | 28 |
| Ezetimibe | Ezetimibe | 68 | 12 |
| Levofloxacin | Levofloxacin | 68 | 55 |
| Lactulose | Lactulose | 67 | 19 |
| Clonazepam | Clonazepam | 66 | 14 |
| Trazodone Hcl | Trazodone Hcl | 66 | 15 |
| Xarelto | Rivaroxaban | 66 | 12 |
| Ibuprofen | Ibuprofen | 62 | 34 |
| Montelukast Sodium | Montelukast Sodium | 59 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 24 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 58 | 57 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 13 |
| Santyl | Collagenase Clostridium Hist. | 53 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 53 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 28 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 27 |
| Brimonidine Tartrate | Brimonidine Tartrate | 49 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 44 | 11 |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | suppressed |
| Nystatin | Nystatin | 41 | 22 |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 16 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 37 | 28 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 37 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Mupirocin | Mupirocin | 35 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Ketoconazole | Ketoconazole | 34 | 18 |
| Meloxicam | Meloxicam | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 33 | suppressed |
| Folic Acid | Folic Acid | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Prednisone | Prednisone | 29 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Haloperidol Decanoate | Haloperidol Decanoate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Enulose | Lactulose | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Safetyglide Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 15 |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Vancomycin Hcl-0.9% Nacl | Vancomycin/0.9 % Sod Chloride | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $770.44 · 12 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, COMIRNATY, DUPIXENT, FASENRA, HYQVIA, NUCALA, PREVNAR 20, PURIFIED CORTROPHIN GEL, TEZSPIRE, Veklury, WAKIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error